<DOC>
	<DOCNO>NCT02312297</DOCNO>
	<brief_summary>The study conduct open-label , balance , randomize , two-treatment , two-period , two-sequence , single-dose , crossover , bioequivalence study compare Minocycline hydrochloride extend release tablet 135 mg manufacture OHM Laboratories Inc. SolodynTM extend release tablet 135 mg manufacture AAI Pharma , Inc Wilmington , NC 28405 manufacture Medicis , The Dermatology Company Scottsdale , AZ 85258 healthy , adult , male , human subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Minocycline HCl 135 mg ER Tablet Sunder Fasting Conditions</brief_title>
	<detailed_description>Test drug abuse ( opiates cannabinoids ) urine breath test alcohol carry prior admission period study . Following overnight fast least 10 hour , single oral dose minocycline hydrochloride extend release tablet 135 mg either test reference formulation administer period study , along 240 mL drink water ambient temperature low light condition supervision train study personnel . During course study , safety parameter assess vital sign , clinical examination , medical history clinical laboratory safety test ( hematology , biochemical parameter , serology urine analysis ) baseline . Adverse event monitoring do throughout study . Laboratory parameter hematology biochemistry ( except blood glucose cholesterol ) repeat end study .</detailed_description>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Volunteers meet follow criterion include study 1 . Were age range 1845 year 2 . Were neither overweight underweight height per Life Insurance Corporation India height/weight chart nonmedical case 3 . Had voluntarily give write informed consent participate study 4 . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study 5 . Male subject : Whose female partner ( ) was/were pregnant was/were plan become pregnant Whose female partner ( ) was/were use least one highly effective one acceptable method birth control ( time ) duration study 2 week completion study , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence . Dual method contraception must use study 2 week discontinuation Whose female partner surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) Those use condom even vasectomy do ; study 2 week completion study 1 . Hypersensitivity minocycline relate group drug drug 2 . History diarrhoea last one week antibiotic induce diarrhoea 3 . Frequent episode light headedness , vertigo dizziness precede one week 4 . History photosensitivity 5 . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination 6 . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes glaucoma , headinjury coma 7 . History psychiatric illness , may impair ability provide write informed consent 8 . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection 9 . Presence value acceptable limit haemoglobin , total white blood cell count , differential WBC count platelet count 10 . Positive urinary screen test drug abuse ( opiates cannabinoids ) 11 . Presence value acceptable limit serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol 12 . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) 13 . Clinically abnormal ECG Chest Xray 14 . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period 15 . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period 16 . Use enzyme modifying drug within 30 day prior Day 1 study 17 . Participation clinical trial within 12 week precede Day 1 study 18 . Subjects , completion study , would donate /or lose 350 ml blood past 3 month study participation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>